Skip to main content
. Author manuscript; available in PMC: 2021 Apr 16.
Published in final edited form as: J Thorac Oncol. 2018 Oct 10;14(2):237–244. doi: 10.1016/j.jtho.2018.10.003

Table 3.

Treatment-Related Adverse Events

Event, n (%) Third-or Later-Line Nivolumab (n = 109)
Any Grade Grade 3–4
Any event 60 (55.0) 13 (11.9)
Any serious event 9 (8.3) 8 (7.3)
Any event leading to discontinuation 3 (2.8) 3 (2.8)
Most frequent events (≥5%)
 Pruritus 14 (12.8) 0
 Fatigue 11 (10.1) 1 (0.9)
 Nausea 8 (7.3) 0
 Rash 7 (6.4) 1 (0.9)
 Diarrhea 7 (6.4) 0
 Decreased appetite 6 (5.5) 1 (0.9)

Data are based on a database lock date of November 6, 2017. Safety analysis included all patients who received at least one dose of the study drug. Includes events reported from the time of the first dose of study drug to 30 days after the last dose.

HHS Vulnerability Disclosure